Skip to main content
Therapeutics and Clinical Risk Management logoLink to Therapeutics and Clinical Risk Management
. 2019 Oct 11;15:1207. doi: 10.2147/TCRM.S232419

Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum]

PMCID: PMC6795023  PMID: 31696867

Shiferaw D, Faruqi S. Ther Clin Risk Manag. 2019;15:1029–1040.

Following a review of our paper post-publication, we found an error had been introduced during the typesetting process.

On page 1029, the first sentence of the introduction section reads as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately ct 380,000 people worldwide.1” This should read as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately 80,000 people worldwide.1”


Articles from Therapeutics and Clinical Risk Management are provided here courtesy of Dove Press

RESOURCES